AU731756B2 - Composition, for the treatment of asthma, containing loratadine and a decongestant - Google Patents

Composition, for the treatment of asthma, containing loratadine and a decongestant Download PDF

Info

Publication number
AU731756B2
AU731756B2 AU49953/97A AU4995397A AU731756B2 AU 731756 B2 AU731756 B2 AU 731756B2 AU 49953/97 A AU49953/97 A AU 49953/97A AU 4995397 A AU4995397 A AU 4995397A AU 731756 B2 AU731756 B2 AU 731756B2
Authority
AU
Australia
Prior art keywords
loratadine
decongestant
pseudoephedrine
administered
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU49953/97A
Other languages
English (en)
Other versions
AU4995397A (en
Inventor
Alan G. Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU4995397A publication Critical patent/AU4995397A/en
Application granted granted Critical
Publication of AU731756B2 publication Critical patent/AU731756B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU49953/97A 1996-10-31 1997-10-29 Composition, for the treatment of asthma, containing loratadine and a decongestant Ceased AU731756B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73966996A 1996-10-31 1996-10-31
US08/739669 1996-10-31
PCT/US1997/019158 WO1998018470A1 (en) 1996-10-31 1997-10-29 Composition, for the treatment of asthma, containing loratadine and a decongestant

Publications (2)

Publication Number Publication Date
AU4995397A AU4995397A (en) 1998-05-22
AU731756B2 true AU731756B2 (en) 2001-04-05

Family

ID=24973307

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49953/97A Ceased AU731756B2 (en) 1996-10-31 1997-10-29 Composition, for the treatment of asthma, containing loratadine and a decongestant

Country Status (21)

Country Link
EP (1) EP0941091A1 (xx)
JP (1) JP2000505104A (xx)
KR (1) KR20000052922A (xx)
CN (1) CN1235545A (xx)
AR (1) AR008908A1 (xx)
AU (1) AU731756B2 (xx)
BR (1) BR9712705A (xx)
CA (1) CA2268546A1 (xx)
CO (1) CO4910128A1 (xx)
CZ (1) CZ150999A3 (xx)
HU (1) HUP9904075A3 (xx)
ID (1) ID23431A (xx)
IL (1) IL129662A0 (xx)
NO (1) NO992062D0 (xx)
NZ (1) NZ335078A (xx)
PE (1) PE11399A1 (xx)
PL (1) PL333056A1 (xx)
SK (1) SK54599A3 (xx)
TR (1) TR199901003T2 (xx)
WO (1) WO1998018470A1 (xx)
ZA (1) ZA979731B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021556A1 (en) * 1997-10-29 1999-05-06 J-Med Pharmaceuticals, Inc. Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
IT1303671B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
CO5271713A1 (es) * 1998-09-10 2003-04-30 Schering Corp Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
KR100505899B1 (ko) * 1999-02-23 2005-08-01 주식회사유한양행 로라타딘과 슈도에페드린을 함유한 캅셀제 조성물
ATE253354T1 (de) * 1999-02-23 2003-11-15 Yuhan Corp Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
AU3924500A (en) * 1999-03-29 2000-10-16 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
WO2001045676A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
WO2001078782A1 (en) * 2000-04-14 2001-10-25 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
PE20020055A1 (es) * 2000-05-25 2002-02-12 Schering Corp Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal
CN1518448A (zh) * 2001-06-20 2004-08-04 ���鹫˾ 用于治疗鼻充血和鼻塞的抗组胺剂
CA2612179C (en) 2005-06-17 2016-08-02 Aft Pharmaceuticals Limited A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion
BRPI0712532A2 (pt) * 2006-06-01 2013-04-02 Schering Plough Healthcare Prod Inc formulaÇÕes e composiÇÕes farmacÊuticas de fenilefrina para absorÇço colânica
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
KR101540191B1 (ko) * 2014-02-24 2015-07-28 성균관대학교산학협력단 로라타딘을 포함하는 항염증용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1110397A (en) * 1964-10-02 1968-04-18 Mead Johnson & Co Ephedrine composition
WO1994009761A1 (en) * 1992-10-23 1994-05-11 Schering Corporation Stable extended release oral dosage composition
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1110397A (en) * 1964-10-02 1968-04-18 Mead Johnson & Co Ephedrine composition
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
WO1994009761A1 (en) * 1992-10-23 1994-05-11 Schering Corporation Stable extended release oral dosage composition

Also Published As

Publication number Publication date
ZA979731B (en) 1998-04-29
NO992062L (no) 1999-04-29
JP2000505104A (ja) 2000-04-25
AR008908A1 (es) 2000-02-23
CN1235545A (zh) 1999-11-17
ID23431A (id) 2000-04-20
KR20000052922A (ko) 2000-08-25
SK54599A3 (en) 2000-08-14
HUP9904075A3 (en) 2002-02-28
TR199901003T2 (xx) 1999-07-21
BR9712705A (pt) 1999-10-26
CZ150999A3 (cs) 1999-10-13
CA2268546A1 (en) 1998-05-07
HUP9904075A2 (hu) 2000-05-28
WO1998018470A1 (en) 1998-05-07
NZ335078A (en) 2000-10-27
AU4995397A (en) 1998-05-22
IL129662A0 (en) 2000-02-29
PE11399A1 (es) 1999-02-09
CO4910128A1 (es) 2000-04-24
NO992062D0 (no) 1999-04-29
PL333056A1 (en) 1999-11-08
EP0941091A1 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
AU731756B2 (en) Composition, for the treatment of asthma, containing loratadine and a decongestant
EP1446119B1 (en) Compositions comprising ipatropium and xylometazoline for treatment of the common cold
Aaronson Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma
KR101841442B1 (ko) 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
US20060276495A1 (en) Treatment methods of nasal congestion and nasal obstruction
ZA200500152B (en) Use of reboxetine for the treatment of hot flashes
Bousquet et al. A 12‐week, placebo‐controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis
Georgitis et al. Ipratropium bromide nasal spray in non‐allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life
Kilfeather et al. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft MistTM Inhaler in patients with COPD
von Berg et al. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat® Soft Mist™ Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma
CA2420532A1 (en) Pharmaceutical formulation of salmeterol and fluticasone propionate
Ishizuka et al. Gender and age risks for hoarseness and dysphonia with use of a dry powder fluticasone propionate inhaler in asthma.
Corren et al. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions
EP2121021A2 (en) Methods for treating nasal congestion in hypertensive or diabetic patients
MXPA99003936A (en) Composition, for the treatment of asthma, containing loratadine and a decongestant
Bianco et al. Effectiveness of nedocromil sodium versus placebo as additions to routine asthma maintenance therapy: a multicentre, double-blind, group comparative trial
EP1569650B1 (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
EP1109557B1 (en) Use of cetirizine for preventing the onset of asthma
WO2008085392A1 (en) Methods for treating nasal congestion in hepatically impaired patients
Frew et al. Effects of 4-week treatment with low-dose budesonide (100 μg BID) from a novel inhaler AirmaxTM and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma
White et al. Comparative effects of fexofenadine and montelukast on allergen-induced wheal and flare
McDonald et al. Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstruction
JP2003048834A (ja) 医薬組成物
Tan et al. Double‐blind comparison of the protective effect of sodium cromoglycate and ketotifen on exercise‐induced asthma in adults
Chuchalin et al. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler™) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer®) in children with persistent asthma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired